Celso de Oliveira Rezende Junior
Overview
Explore the profile of Celso de Oliveira Rezende Junior including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Cunha I, da Silva Oliveira D, Calefi G, Sousa Silva N, Martins C, de Oliveira Rezende Junior C, et al.
Eur J Med Chem
. 2024 Dec;
284():117197.
PMID: 39731789
Antimicrobial resistance is currently one of the biggest challenges in controlling infectious diseases and was listed among the top 10 threats to global health by the World Health Organization (WHO)...
2.
Januario M, de Oliveira Rezende Junior C, Castro-Gamboa I
Chem Biodivers
. 2024 Dec;
:e202402517.
PMID: 39714443
Dengue, a mosquito-borne disease transmitted by Aedes mosquitoes, is a significant global health concern. Despite extensive research, effective treatments remain limited. The indole nucleus, known for its diverse pharmacological properties,...
3.
da Silva F, Cassiano Martinho A, Ferreira H, Siqueira R, Arruda V, Guerra J, et al.
Molecules
. 2024 Sep;
29(18).
PMID: 39339466
Breast cancer (BC) is the most common cancer in women, and is characterized by its histological and molecular heterogeneity. Luminal BC is an estrogen receptor-positive subtype, with varied clinical courses....
4.
da Silva Oliveira D, Sousa Silva N, Jacques Dit Lapierre T, de Souza S, Ferreira Brito N, Cassiano Martinho A, et al.
Chem Biodivers
. 2024 Sep;
22(2):e202402100.
PMID: 39327235
Microorganisms can induce diseases with significant clinical implications for human health. Multidrug-resistant microorganisms have been on the rise worldwide over the past few decades, and no new antibiotics have been...
5.
da Silva Oliveira D, Paz F, Ferreira Brito N, Kruger A, Cassiano Martinho A, Jacques Dit Lapierre T, et al.
Eur J Med Chem
. 2024 Jun;
275:116621.
PMID: 38944935
An optimization of the pyridylpiperazine series against Plasmodium falciparum has been performed, exploring a structure-activity relationship carried out on the toluyl fragment of hit 1, a compound with low micromolar...
6.
Espinoza-Chavez R, de Oliveira Rezende Junior C, De Souza M, Consolin Chelucci R, Michelan-Duarte S, Krogh R, et al.
ChemMedChem
. 2024 Jun;
19(20):e202400293.
PMID: 38924252
This study introduces further insights from the hit-to-lead optimization process involving a series of benzimidazole derivatives acting as inhibitors of the cruzain enzyme, which targets Trypanosoma cruzi, the causative parasite...
7.
Murta S, Santana P, Jacques Dit Lapierre T, Penteado A, El Hajje M, Navarro Vinha T, et al.
Expert Opin Drug Discov
. 2024 May;
19(6):741-753.
PMID: 38715393
Introduction: Benznidazole, the drug of choice for treating Chagas Disease (CD), has significant limitations, such as poor cure efficacy, mainly in the chronic phase of CD, association with side effects,...
8.
Freitas de Lima Hercos G, Cruz M, Cassiano Martinho A, Resende D, Farago Nascimento D, Macruz P, et al.
Bioorg Med Chem
. 2024 Apr;
105:117736.
PMID: 38677111
Leishmaniasis and Chagas disease are neglected tropical diseases caused by Trypanosomatidae parasites. Given the numerous limitations associated with current treatments, such as extended treatment duration, variable efficacy, and severe side...
9.
Jacques Dit Lapierre T, Nascimento Farago D, Cruz M, Resende D, de Oliveira A, Dos Santos B, et al.
Chem Biol Drug Des
. 2024 Apr;
103(4):e14525.
PMID: 38627214
An early exploration of the benzothiazole class against two kinetoplastid parasites, Leishmania infantum and Trypanosoma cruzi, has been performed after the identification of a benzothiazole derivative as a suitable antileishmanial...
10.
Espinoza-Chavez R, de Oliveira Rezende Junior C, De Souza M, Pauli I, Valli M, Gomes Ferreira L, et al.
Future Med Chem
. 2024 Jan;
16(3):253-269.
PMID: 38193294
Chagas disease is caused by the parasite , and the lack of effective and safe treatments makes identifying new classes of compounds with anti- activity of paramount importance. Hit-to-lead exploration...